PA
PAR.AU Paradigm Biopharmaceuticals Ltd
- Market cap
- AUD 153M
- P/E
- -
- P/B
- 44.22x
- ROE
- -1,623.0%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PAR.AU undervalued?
Graham numberThe Graham number of Paradigm Biopharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Paradigm Biopharmaceuticals Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-1,623.0%), below 10%.
ROA 0/1
Return on assets (-184.4%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-155.1%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 19.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (216.4%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (44.2x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Paradigm Biopharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Full company profileParadigm Biopharmaceuticals Ltd financial statements
Paradigm Biopharmaceuticals Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.82M | 2.68M | 2.98M | 4.70M | 20.6K | 79.2K | 46.8K | 65.8K | 52.1K | 80.2K |
| Gross Profit | 1.81M | 2.67M | 2.98M | -213K | -78.6K | -64.5K | 27.9K | 56.8K | -19.9K | -82.4K |
| Operating Income | -6.12M | -8.93M | -8.75M | -17.0M | -42.3M | -47.0M | -51.9M | -65.2M | -22.9M | -61.1M |
| EBITDA | -6.12M | -8.93M | -8.95M | -15.7M | -42.4M | -46.8M | -51.9M | -64.5M | -25.2M | -61.0M |
| Net Income | -4.28M | -6.19M | -15.6M | -12.3M | -34.3M | -39.3M | -51.9M | -58.7M | -18.8M | -56.3M |
| EPS | -0.04 | -0.05 | -0.11 | -0.06 | -0.16 | -0.16 | -0.18 | -0.20 | -0.06 | -0.15 |
| Balance Sheet | ||||||||||
| Total Assets | 14.3M | 15.2M | 85.5M | 112M | 84.8M | 50.7M | 67.1M | 27.4M | 24.6M | 30.6M |
| Total Liabilities | 955K | 1.33M | 2.70M | 4.18M | 6.52M | 8.38M | 13.4M | 3.58M | 3.39M | 27.1M |
| Shareholders' Equity | 13.4M | 13.9M | 82.8M | 108M | 78.3M | 42.3M | 53.7M | 23.8M | 21.2M | 3.47M |
| Cash & Short-term Investments | 2.59M | 2.45M | 78.8M | 105M | 71.1M | 39.7M | 56.4M | 17.9M | 16.8M | 15.4M |
| Total Debt | 36.6K | 36.6K | 36.6K | 874K | 752K | 617K | 342K | 239K | 5.48K | 7.51M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.47M | -6.01M | -6.37M | -10.1M | -34.9M | -32.2M | -45.2M | -65.9M | -16.0M | -43.7M |
| Capital Expenditure | 20.0K | 3.05K | 17.8K | 131K | 31.6K | 4.00 | 0.00 | 65.9M | 5.00 | 491K |
| Free Cash Flow | -4.49M | -6.02M | -6.38M | -10.2M | -35.0M | -32.2M | -45.2M | -65.9M | -16.0M | -43.7M |
| Ratios | ||||||||||
| ROE | -31.9% | -44.6% | -18.9% | -11.4% | -43.8% | -92.8% | -96.7% | -246.4% | -88.6% | -1,623.0% |
| ROA | -29.8% | -40.7% | -18.3% | -10.9% | -40.4% | -77.4% | -77.4% | -214.1% | -76.4% | -184.4% |
| Net Profit Margin | -234.5% | -230.7% | -523.7% | -261.9% | -166,895.4% | -49,543.1% | -111,013.7% | -89,138.3% | -36,014.5% | -70,282.3% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 2.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Paradigm Biopharmaceuticals Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 58.9M | 0.20 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 2.59M | 0.01 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1097:1067 on Nov 1, 2023.
Who owns Paradigm Biopharmaceuticals Ltd
- Insiders 14.31%
- Institutions 4.83%
- Public & others 80.86%
- Shares outstanding 626M
- Free float 530M
Top funds holding PAR.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 2.07M | 0.91% | - | Oct 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 1.26M | 0.56% | - | Dec 2020 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 546K | 0.24% | - | Oct 2020 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 287K | 0.13% | - | Nov 2020 |
| Vanguard International Stock Index-Pacific Stock Index | 183K | 0.08% | - | Jan 2021 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 96.3K | 0.04% | - | Feb 2021 |
| Allianz Fds Multi Strategy Tr-AllianzGI International Small Cap Fd | 91.5K | 0.04% | - | Dec 2020 |
| Vanguard Intl Equity Index - Total World Stock Index Fd | 65.6K | 0.03% | - | Oct 2020 |
| Allianz Fds-AllianzGI Global Small Cap Fd | 36.4K | 0.02% | - | Dec 2020 |
Paradigm Biopharmaceuticals Ltd company profile
- Company name
- Paradigm Biopharmaceuticals Ltd
- Ticker
- PAR.AU
- ISIN
- AU000000PAR5
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 500 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9629 5566
- Website
- paradigmbiopharma.com
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Paradigm Biopharmaceuticals Ltd management
8- Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTCFounder, MD & Executive Chairman · born 1959
- Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.Company Secretary & CFO · born 1982
- Dr. Ravi KrishnanChief Scientific Officer
- Mr. Simon WhiteDirector of Investor Relations
- Dr. Michael ImperialeGlobal Head of Drug Safety & MPS
- Dr. Donna L. Skerrett M.D., MSChief Medical Officer · born 1957
- Ms. Beverley HuttmannCommercial Head
- Dr. Mukesh AhujaGlobal Clinical Head of OA